Page 3 - Johna Mclean News Today

State of Alaska Department of Revenue grew its position in Toll Brothers, Inc. (NYSE:TOL – Free Report) by 1.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 12,996 shares of the construction company’s stock after purchasing an additional 235 shares during the quarter. State of Alaska Department of Revenue’s holdings in Toll Brothers were […]

Bremer Bank National Association boosted its stake in Toll Brothers, Inc. (NYSE:TOL – Free Report) by 138.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,176 shares of the construction company’s stock after purchasing an additional 15,768 shares during the […]

Toll Brothers, Inc. (NYSE:TOL – Get Free Report) Director John A. Mclean sold 3,863 shares of Toll Brothers stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $103.57, for a total transaction of $400,090.91. Following the sale, the director now owns 10,091 shares of the company’s stock, […]

Toll Brothers, Inc. (NYSE:TOL – Get Free Report) Director John A. Mclean sold 3,863 shares of the stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $103.57, for a total value of $400,090.91. Following the transaction, the director now directly owns 10,091 shares of the […]

SelectScience members are invited to join this exclusive online gathering of scientific experts and manufacturers in analytical research and development

SelectScience members are invited to join this exclusive online gathering of scientific experts and manufacturers in analytical research and development

SelectScience members are invited to join this exclusive online gathering of scientific experts and manufacturers in analytical research and development

SelectScience is bringing together leaders in analytical research and development through our online conference

SelectScience members are invited to join this exclusive online gathering of scientific experts and manufacturers in analytical research and development

[co-authors: Kim Beane, and Daniel Meckley] Cancer is a horribly painful and debilitating illness, but would you ever call it “diabolical”? What about “conniving”? You might after you hear about the latest research out of Vanderbilt University showing that cancer cells adjust their metabolic profile to evade the effects of treatment. A team of scientists has shown certain melanomas that initially respond well to a particular treatment, ultimately reprogram their metabolism to defeat the...